Background: Rapid, reproducible, and easily run methods with high sensitivity and specificity are required for mutation screening of clinical samples. We evaluated the Enzymatic Mutation Detection (EMD TM ) method by analysis of archival cDNA from 203 breast cancer patients and comparison with results of cDNA-based sequencing of the tumor suppressor gene p53. Methods: The EMD technology uses the T4 endonuclease VII, which cleaves double-stranded DNA at sites where a DNA mismatch is present because of mispairing or an insertion/deletion of nucleotides. The EMD analyses were carried out by dividing the p53 gene into two overlapping fragments that were analyzed separately. After PCR amplification, the fragments were hybridized with wild-type p53 and subsequently exposed to the EMD enzyme. Cleavage products were analyzed and scored using an ALF TM automated DNA sequencer and ALFwin Fragment Analyzer software (Ver. 1.02). Results: The EMD technique had sensitivities of 45% and 64% and specificities of 83% and 84% for the two fragments, respectively. Patients with EMD-positive, wild-type p53 tumors had a survival similar to that of patients with EMD-negative, wild-type p53 tumors. Node-positive patients with p53 mutated tumors according to sequencing had a statistically significantly worse overall survival than those with p53 wild-type tumors (P ‫؍‬ 0.016), whereas this difference in survival was not detected when p53 status was determined with EMD (P ‫؍‬ 0.47).
The tumor suppressor p53 gene is located on the short arm of chromosome 17. DNA-damaging agents, such as carcinogens, cytostatics, radiation, and ultraviolet light will typically lead to activation of the p53 gene (1 ) . Accumulating evidence suggests that the tumor suppressor p53 plays a central part in intracellular resistance against malignant transformation and tumor progression (1) (2) (3) (4) . Mutations in the p53 gene are among the most common genetic abnormalities described in human cancer to date. Studies on primary breast cancer have shown worse outcomes for patients with p53 protein overexpression (5, 6 ) or mutations of the p53 gene (7, 8 ) in their tumors. Previous studies have indicated that p53 mutations may be an early event in breast cancer development, and these mutations have been found in 20 -25% of invasive primary breast cancers (8, 9 ) .
The use of sequence analysis for mutation detection is considered an accurate but high-cost and labor-intensive technique. Protein-based methods, immunohistochemistry, and the luminometric immunoassay have lower sensitivity and specificity and provide less optimal prognostic information (8, 10 -12 ) . Accordingly, an accurate mutation-screening method that minimizes sequencing is desired.
EMD was developed for the rapid scanning of DNA to find polymorphisms and mutations. The technology uses an enzyme, the T4 endonuclease VII, that is involved in the recognition of DNA mismatches. This enzyme usually is responsible for recognition and cleavage of branched DNA intermediates formed during DNA replication and packaging. It cleaves double-stranded DNA at sites where a DNA "bubble" is formed because of mispairing or an insertion/deletion of nucleotides.
The EMD technology is claimed not only to detect the presence of a mutation in a sample, but also the mutation site. EMD has been accurate and effective in studies based on genomic DNA of several different genes (13) (14) (15) (16) and has been shown to detect all types of mismatches. Proofof-principle studies have been performed on the tumor suppressor gene p53 (13, (17) (18) (19) .
Materials and Methods study population and tumor samples
The study population consisted of 315 primary breast cancer patients derived from a population-based cohort diagnosed during 1987-1989 (8 ) . The study was approved by the Ethical Committee of the University of Uppsala. The patients received primary therapy with surgery, radiotherapy, and systemic adjuvant therapy, depending on disease state as described previously (8 ) . The clinical follow-up was carried out as described previously (8, 10 ) , and we recently updated the patient material with respect to relapses and survival. RNA was extracted from freshly frozen tumors from these patients and converted into the corresponding cDNAs for subsequent analysis during 1993-1994 (10 ) . The remaining cDNAs were stored in 1.5-mL Eppendorf tubes at Ϫ20°C. Of the original 315 cDNA samples, 203 still had sufficient amounts of cDNA left and were, therefore, included in this study. For a more detailed description, see Fig. 1 . Two cell lines with defined p53 mutations, one in each fragment (see below), were used as positive controls.
sequence analysis
The sequencing reactions performed on this breast cancer material have been described previously (10 ) . In short, using four overlapping gene-specific primer-pairs, covering all 11 p53 exons, we amplified the p53 gene by PCR. One primer of each pair was modified by a biotin molecule, generating biotinylated PCR fragments. An aliquot of each reaction was used to run an agarose gel for quality and quantity control. The remainder of each reaction was captured on streptavidin-coated plastic combs and subjected to solid-phase dideoxy sequencing using the Amersham Pharmacia Biotech AutoLoad reagent set. The reactions were directly loaded onto an ALF TM automated DNA sequencer and analyzed by electrophoresis. Each deviation in the sequence causing an amino acid exchange was scored as a mutation. Each mutation was verified by reamplification and sequencing of the fragment using the cDNA preparation as the starting material.
emd primer design and pcr amplification
The strategy chosen for the EMD analysis was to PCR amplify the entire coding region of p53 using a nested approach with a cDNA as the template. The first round of PCR was carried out using primers PN-8 and PN-9, which amplify a 1379-bp fragment containing all coding exons of the p53 gene. The second round of PCR was carried out in two separate reactions: the 5Ј half of p53 (fragment 1-2) was amplified with primers GA-1 and GA-2 (759 bp) and the 3Ј half (fragment 3-4) was amplified with primers P34-1 and P34-2 (703 bp). The two fragments together covered the complete coding sequence of p53 with a 173-bp overlap. PCR primers used. In the first round of PCR (PCR1), the following primers were used for both fragments: PN-8 (5Ј-GTGCTTTCCACGACGGTGAC-3Ј) and PN-9 (5Ј-CA-AATGGAAGTCCTGGGTGCTT-3Ј). In the second round of PCR (PCR2), the primers used for fragment 1-2 were GA-1 (5Ј-CCAGACTGCCTTCCGGGTCA-3Ј) and GA-2 (5Ј-CCGCCCATGCAGGAACTGTTAC-3Ј), and the primers used for fragment 3-4 were P34-1 (5Ј-CTGGCCCCTC-CTCAGCATCTTAT-3Ј) and P34-2 (5Ј-TCAAAGACCCA-AAACCCAAAATG-3Ј).
Amplification conditions and cycling protocols. The amplification conditions for PCR1 were 1ϫ Buffer II (PerkinElmer), 1.5 mM MgCl 2 , 0.2 mM dNTP, 4 pmol of each primer, 0.5 L of cDNA, and 1 U of AmpliTaq Gold (Perkin-Elmer) in a total volume of 20 L. For PCR2 (the same for both fragments), the conditions were 1ϫ Buffer II (Perkin-Elmer), 1.5 mM MgCl 2 , 0.2 mM dNTP, 4 pmol of each primer, 1 L of PCR1 product, and 0.75 U of AmpliTaq Gold in a total volume of 20 L.
The cycling protocols for PCR1 were as follows: 1 cycle at 95°C for 9 min; 10 cycles at 95°C for 30 s, 72°C for 30 s, and 72°C for 45 s; 10 cycles at 95°C for 30 s, 72°C ramped to 67°C at 0.5°C/cycle for 30 s, and 72°C for 45 s; 20 cycles at 95°C for 30 s, 66°C for 30 s, and 72°C for 45 s; 1 cycle at 72°C for 5 min; and then hold at 22°C.
The corresponding protocols for PCR2 were 1 cycle at 95°C for 9 min; 40 cycles at 95°C for 15 s, 66°C for 30 s, and 72°C for 45 s; 1 cycle at 72°C for 5 min; and then hold at 22°C. Both reactions were performed on a PerkinElmer 9700 thermocycler.
After amplification, all PCR fragments were checked for quality and quantity by electrophoresis on a 1% agarose gel.
emd reaction and analysis
The human small-cell lung cancer cell line U-1285 (20 ) and human breast cancer cell line MDA-MB-231 (21 ) were used as positive controls for fragments 1-2 and 3-4, respectively. MDA-MB-231 (MDA) has a point mutation in codon 280 (G/A), and U-1285 has a 21-bp deletion starting in codon 126 (T. Norberg, unpublished data).
By amplifying fragment 1-2 from MDA and fragment 3-4 from U-1285, two probes were generated, both of which were confirmed as wild type. The probes were purified according to the manufacturer's recommendations, and the concentration of each was determined using a spectrophotometer. Amersham Pharmacia Biotech AB (Uppsala, Sweden) supplied all protocols and EMD reaction consumables.
A negative control without the EMD enzyme was included for each sample during the EMD reaction to enable the identification of possible sample contaminants. Running two identical reactions per sample, omitting only the EMD enzyme in the control, generated the EMD-negative controls. We then set two criteria for scoring a sample as positive: (a) the generated peak should deviate from the other samples; and (b) the peak should not be present in the EMD-negative control for the tested sample.
The EMD reactions were performed according to the manufacturer's recommendations (reagent set supplied) with a few modifications by us that provided better resolution of our samples. All samples, including the positive controls, were treated identically throughout the process. In short, the probe and sample (or positive control) were mixed and hybridized by heating to 95°C for 5 min followed by 5 min of incubation at room temperature. The reaction was split into two equal parts (7.5 L ϩ 7.5 L); one received 2.5 L of diluted EMD enzyme (250 U per reaction), and the other received only enzyme dilution buffer. After incubation at 37°C for 30 
Results
From the 315 breast cancer patients, we had cDNA remaining from 203 patients. We could successfully amplify 197 samples with fragment 1-2 and 182 samples with fragment 3-4 ( Fig. 1) . For 179 samples, both the fragments could be amplified, and the resulting p53 data could consequently be used in survival calculations. Two different operators (T. N. and L. L.) evaluated the EMD results. All of the samples were coded so that the operators had no prior knowledge of the mutational status of the samples. In the first EMD round, deviating peak patterns were found in 68 of 197 fragment 1-2 samples, whereas no deviations were found in 129 samples. The positive samples were reanalyzed, starting from cDNA. We could confirm the peak pattern deviations in 40 of the 68 samples. These samples were considered as EMD positives. For fragment 3-4, we could detect 61 positive and 121 negative samples in the first round. After the confirmation round, 40 of the 61 initial samples remained positive and were scored as EMD positives.
After all samples were analyzed and computerized, the study code was broken. We then compared the EMD results with the corresponding cDNA sequencing results. If we consider sequencing as the "gold standard" for p53 determinations, the EMD method led to 31 false-positive results and 11 false-negative samples for fragment 1-2 from a total of 40 positive and 157 negative samples. As summarized in Table 1 , this gave a sensitivity [true positives/(true positives ϩ false negatives)] of 45% [95% confidence interval (CI), 23-68%] and a specificity [true negatives/(true negatives ϩ false-positives)] of 82% (95% CI, 76 -88%). In total, the corresponding values for fragment 3-4 were 26 false positives among 40 positive samples and 8 false negatives among 140 negative samples. This gave a sensitivity of 64% (95% CI, 41-83%) and a specificity of 84% (95% CI, 77-89%).
By analyzing the sizes of the peaks in the positive samples, we found a reasonably good correlation (approximately Ϯ 25 bases) with the site of mutation as determined by sequencing. This was especially true for fragment 3-4 ( Table 2 ). For many of the cases, however, there were additional peaks, and only one of the expected cleavage products was identified for some. 
unmodified method
To investigate the possibility that our modification of the enzyme to improve the resolution of the EMD data from our samples may somehow have interfered with the overall results of the EMD technique, we ran 106 samples with fragment 1-2 using the recommended enzyme amounts. This gave a sensitivity of 33% (95% CI, 8 -70%) and a specificity of 87% (95% CI, 78 -93%), whereas our modified procedure had a sensitivity and a specificity of 45% (95% CI, 23-68%) and 82% (95% CI, 76 -88%), respectively.
assurance of sample quality
The sample quality in terms of PCR quantity and quality varied in the analyzed cDNAs. We included samples for EMD analysis for which a band the correct size could be visualized on an agarose gel. Some samples, however, had a weak intensity or additional bands. The latter could be compensated for by running the EMD negative controls as described above. In addition, by calculating sensitivity and specificity values for a subset of high-quality PCR products (Fig. 2) , we could challenge the argument that the EMD reactions were conducted on samples of insufficient quality. By selecting the highest quality PCR products for fragment 3-4, we identified 82 samples of the total of 182. The sensitivity and specificity values for these high-quality samples were 72% (95% CI, 39 -94%) and 84% (95% CI, 74 -92%), respectively (Table 3) , compared with the sensitivity of 64% (95% CI, 41-83%) and specificity of 84% (95% CI, 77-89%) obtained for all fragment 3-4 samples, as stated above.
To further verify the integrity of our material, we resequenced a subset of the EMD false-negative samples, using the original method (10 ) , and could confirm 9 of 10 mutations previously scored with sequencing. We failed to confirm one mutation (a 2-bp deletion in codon 214). 
correlation with clinical outcome
For a clinical application of the EMD technique, a correlation between the EMD-generated data and patient outcome would be the primary objective. We therefore compared the survival curves, according to Kaplan-Meier, obtained by p53 sequencing (wild-type and mutated) and EMD analysis (positive and negative), respectively. We first analyzed the overall survival for all 179 evaluable patients, divided into four subgroups: (a) wild-type and EMD negative, (b) wild-type and EMD positive, (c) mutated and EMD negative, and (d) wild-type and EMD positive. As shown in Fig. 3A , the sequencing-generated p53 data separated, to some degree, the four survival curves into two main groups with better or poorer outcomes, although the differences between all four subgroups were not statistically significant (P ϭ 0.19). When we analyzed the subgroup of patients that were diagnosed with metastases in the axillary lymph nodes, we detected p53 mutations by cDNA sequencing, which clearly conferred statistically significant shorter survival (P ϭ 0.016) compared with wild-type p53 (Fig. 3B) . Such a distinct and statistically significant difference was not observed when the p53 mutations were detected by EMD (P ϭ 0.47), as shown in Fig. 3C .
Discussion
Hopefully, in the future oncological therapies will be tailor-made for the individual patient based on the analysis of relevant prognostic and predictive factors. This will require access to a panel of predictive and prognostic factors. These factors must be determined by methods with high sensitivity and specificity. For p53 analysis, molecular biology-based methods, such as sequencing, have to date been more accurate than protein-based methods (10 -12 ) , and sequencing has often been considered the gold standard for p53 analysis. The primary aim of this investigation was to examine whether EMD could function as a reliable screening tool for detection of p53 mutations because protein-based screening methods failed to fulfill our requirements.
In this study of archival cDNA samples, EMD did not show the impressive sensitivity reported previously for work with genomic DNA (13, 16 ) or cDNA (18 ) as the template. One may argue that (a) the cDNA starting materials were of lower quality because they were collected from 1987 to 1989, and (b) a more recent preparation of cDNA would possibly increase the performance of the EMD technique. However, we deliberately chose these materials because cDNA preparations cannot be generated from all materials, and we believe the quality of a majority of tumor materials used currently may be comparable to ours. A similar study (18, 19 ) of p53 mutations in cDNA reported a sensitivity of 91% and a specificity of 80% for EMD based on 114 samples with the ALFexpress system, which we used; however, the authors had to exclude 64 samples (36% of the 178 samples available) because they did not fulfill the PCR criteria to qualify for EMD analysis. In addition, the authors conducted their study on fragment 3-4 only, which attained the highest values in our study with respect to sensitivity and specificity. Our materials were, however, of sufficient quality to verify 9 of 10 known mutations using solid-phase sequencing. We wanted to conduct the EMD study on the same cDNA samples that we had used previously for solid-phase sequencing (8 ) , thereby minimizing the risk of getting inconsistent results because of sample or sampling inhomogeneity. In addition, we previously have demonstrated on 100 tumor samples from these same materials that 22 of 23 p53 exon mutations were detected by cDNA sequencing compared with sequence analysis of genomic DNA derived from microdissected material (22 ) . This demonstrates a high consistency between two markedly different sequencing approaches.
One may argue that we used the EMD technology under suboptimal conditions because we reduced the enzyme amounts in the reactions. However, after analyzing 106 samples with fragment 1-2 using the recommended enzyme amounts, we achieved a sensitivity and a specificity of 33% and 87%, respectively. Our experimental procedure had a sensitivity of 45% and a specificity of 82%. Furthermore, in all experiments, we included positive and negative controls, and the results were always as predicted. Thus, we conclude that we have analyzed the present material under conditions similar to or better than the recommended protocol.
The EMD technique appears more dependent on highquality PCR than sequencing methods. When we included only PCR products of the highest quality and quantity, the sensitivity for fragment 3-4 was improved from 64% to 72% (Table 3) . To achieve this, however, we had to exclude 60% of the available samples compared with 10% in our initial strategy. With an exclusion rate of that magnitude, no method can be considered satisfactory for mutation screening.
A theoretical possibility, however, could be that the EMD technique might have a higher sensitivity in the detection of p53 abnormalities than cDNA sequencing. The ultimate test would then be to examine whether the prognosis is worse for patients with positive EMD results without a verified p53 mutation compared with patients with wild-type p53 and a negative EMD reaction. However, that was not the case. Survival analyses showed that the EMD-generated data did not correlate with the clinical outcome in any significant way (Fig. 3, A and C) , unlike the sequencing-generated p53 data, which were statistically significant in correlation with survival in the whole patient material (data not shown) and in the lymph node-positive group (Fig. 3B) . The clinical value of EMDgenerated p53 data thus appears limited.
Another conclusion with respect to the EMD technique is that the success rate will vary with the gene fragments analyzed. In this study, we experienced better results with fragment 3-4 than with fragment 1-2, in spite of a higher PCR success rate with fragment 1-2. This indicates that the Clinical Chemistry 47, No. 5, 2001 performance of the EMD reactions will vary depending on the sequence in the fragment to be analyzed.
In conclusion, the requirements for a mutation screening technique should be high specificity, high sensitivity, high throughput, and cost-effectiveness. Our data strongly indicate that EMD does not meet these requirements when used on archival cDNA.
